Hemophilia A Market Trends The report provides a detailed analysis of the current hemophilia A marketed drugs and late-stage pipeline drugs ...

Sanofi acquired the drug when it bought Bioverativ in 2018 for $11.6 billion, and the company has previously said it thinks it has the potential to become a $2 billion-a-year blockbuster.

Sanofi and Sobi’s haemophilia partnership has been under competitive pressure from new therapies like Roche’s antibody Hemlibra, and are hoping that a newly-approved long-acting drug can ...

As multiple companies vie to expand on Alnylam’s success in commercializing RNAi therapeutics, the pioneering company has set ...